SELLAS Life Sciences reported a pro forma cash position of approximately $135.8 million as of early June. Recent warrant exercises significantly bolstered this capital. These reserves provide an operational runway exceeding two years.
The company is currently advancing its SLS009 trial for Acute Myeloid Leukemia (AML). The Phase 3 REGAL study for the GPS treatment is also nearing completion. While the REGAL trial remains a focal point, the broader AML platform serves as the primary long-term value driver.